Ministry of Health and Prevention in UAE procures Epiprotect for a value of approximately 7 MSEK
Ministry of Health and Prevention (”MoHAP”) has published a procurement of Epiprotect to a value of 7 MSEK. The procurement is published since the delivery agreement signed back in 2020 is about to expire and the ministry wants to secure the access to Epiprotect which has been implemented as standard of care in several of the ministry’s hospitals in the country. The volume should be seen as a projected minimum consumption and the actual volume can be increased based on the actual consumption, providing that the procurement leads to an agreement. The procurement specifically states Epiprotect which indicates a high probability that an agreement will be put in place.
MoHAP has 17 hospitals and 77 primary care units in the country. The usage of Epiprotect has increased over time, and since the first delivery agreement was signed with the ministry, it has been renewed on several occasions the past years. The increased usage has therefor resulted in MoHAP now procuring a larger volume of the products within the Epiprotect series.
”The usage of Epiprotect has increased in the country recently, due to the major efforts in marketing by our local team in UAE, both within the private and the public sector. This procurement is a clear sign that the demand of Epiprotect is on the rise and our ambition is to build an even greater demand than what this procurement is indicating. Our estimate is that we with this procurement would have about 1 % of the potential market for our devices in UAE. Our goal is to pass 10 % within 2 years at the same time as we intend to create growth in geographic proximity.” Says the company’s COO Mårten Skog.
This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-09-2022 10:47 CET.
Contact Details
Petter Sivlér – CEO, S2Medical AB (publ)
Telephone: +46 (0)8-70 000 50
E-mail: petter.sivler@s2m.se
Certified Adviser
Vator Securities AB
Telephone +46 (0)8-580 065 99
Website: www.vatorsec.se
E-mail: ca@vatorsec.se
About S2Medical
S2Medical AB (publ) is a medical technology company that develops and sells innovative wound healing products for the entire wound healing process, with a focus on burns and chronic wounds. The company has developed eiratex®, a new cellulose-based material for healing severe burns and chronic wounds. The material heals wounds effectively and thereby reduces both suffering for patients and costs for health care.
Share's ticker: S2M
Share's ISIN-code: SE0011725084